1. 10 Molecules in early development. (1st September 2020) Authors: Furie, Richard Journal: Lupus science & medicine Issue: Volume 7(2020)Supplement 2 Page Start: A6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1107 Immune cell heterogeneity in lupus nephritis kidneys and its relation to histopathological features: lessons from the accelerating medicines partnership (AMP) in SLE Consortium. (14th December 2022) Authors: Arazi, Arnon; Mears, Jospeh; Eisenhaure, Thomas M; Xiao, Qian; Hoover, Paul J; Rao, Deepak A; Berthier, Celine C; Fava, Andrea; Gurajala, Siddarth; Peters, Michael; Jones, Tony; Sakaue, Saori; Apruzzese, William; Barnas, Jennifer L; Fine, Derek; Lederer, James; Furie, Richard; Davidson, Anne; Hil... Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 3 Page Start: A73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 15 Management of lupus nephritis. (6th April 2022) Authors: Furie, Richard Journal: Lupus science & medicine Issue: Volume 9:(2022)supplement 1 Page Start: A8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1702 Patients enrolled in the accelerating medicines partnership (AMP) RA/SLE network with isolated renal disease report minimal quality of life impairment on PROMIS-29 compared to patients with extrarenal symptoms. (14th December 2022) Authors: Carlucci, Philip; Li, Jessica; Gold, Heather T; Deonaraine, Kristina; Fava, Andrea; Buyon, Jill; James, Judith A; Putterman, Chaim; Rao, Deepak; Diamond, Betty; Fine, Derek; Monroy-Trujillo, Jose; Haag, Kristin; Apruzzese, William; Michael Belmont, H; Connery, Sean; Payan-Schober, Fernanda; Furie... Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 3 Page Start: A102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 18 Rare disease manifestations in SLE. (1st September 2020) Authors: Amoura, Zahir; Furie, Richard; Isenberg, David Journal: Lupus science & medicine Issue: Volume 7(2020)Supplement 2 Page Start: A13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 23 New and approved therapies for lupus nephritis: Belimumab and voclosporin. (6th April 2022) Authors: Furie, Richard Journal: Lupus science & medicine Issue: Volume 9:(2022)supplement 1 Page Start: A12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Issue 2 (11th November 2022) Authors: Kalunian, Kenneth C.; Furie, Richard; Morand, Eric F.; Bruce, Ian N.; Manzi, Susan; Tanaka, Yoshiya; Winthrop, Kevin; Hupka, Ihor; Zhang, Lijin (Jinny); Werther, Shanti; Abreu, Gabriel; Hultquist, Micki; Tummala, Raj; Lindholm, Catharina; Al‐Mossawi, Hussein Journal: Arthritis & rheumatology Issue: Volume 75:Issue 2(2023) Page Start: 253 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. AI-18 The effect of belimumab on B cell selection in human SLE. (August 2018) Authors: Huang, Weiqing; Quach, Tam; Dascalu, Cosmin; Liu, Zheng; Leung, Tungming; Han, Jian; Lesser, Martin; Rothstein, Thomas; Furie, Richard; Mackay, Meggan; Aranow, Cynthia; Davidson, Anne Journal: Lupus science & medicine Issue: Volume 5(2018)Supplement 2 Page Start: A9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. An evaluation of anifrolumab for use in adults with systemic lupus erythematosus. (2nd November 2022) Authors: Ahmed, Abdullah Ali; Osman, Naureen; Furie, Richard Journal: Expert review of clinical immunology Issue: Volume 18:Number 11(2022) Page Start: 1095 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Issue 1 (26th November 2018) Authors: Merrill, Joan T; Furie, Richard; Werth, Victoria P; Khamashta, Munther; Drappa, Jorn; Wang, Liangwei; Illei, Gabor; Tummala, Raj Journal: Lupus science & medicine Issue: Volume 5:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗